The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson’s treatment for myasthenia gravis.
About 100,000 people in the U.S. suffer from myasthenia gravis, an autoimmune condition that weakens the skeletal muscles of the mouth, throat, eyes, and limbs.
Although myasthenia gravis comes in various forms, Johnson & Johnson claims that Imaavy works for over 90% of patients.
In 2020, Johnson & Johnson paid $6.5 billion to acquire Momenta, which included Imaavy. A 1,200 mg vial usually is priced at $12,480.
According to the findings of a 24-week late-stage clinical trial, Imaavy considerably improved the ability of patients with myasthenia gravis to carry out everyday tasks like speaking, breathing, and chewing. This FDA approval was based on those findings.
